Cargando…

Breast cancer chemotherapy treatment monitoring based on serum sample Raman spectroscopy

In this paper, breast cancer patients were monitored throughout their chemotherapy treatments (CHT), with blood serum sample Raman spectroscopy and multivariate analysis, approximately for a year. First of all, we discriminate between healthy and clinically diagnosed breast cancer patients. Breast c...

Descripción completa

Detalles Bibliográficos
Autores principales: Torre-Gutiérrez, L. G. De la, Martínez-Zérega, B. E., Oseguera-Galindo, D. O., Aguilar-Lemarroy, A., Jave-Suárez, L. F., Torres-González, L. A., González-Solís, J. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562073/
https://www.ncbi.nlm.nih.gov/pubmed/36239879
http://dx.doi.org/10.1007/s10103-022-03646-5
_version_ 1784808090849247232
author Torre-Gutiérrez, L. G. De la
Martínez-Zérega, B. E.
Oseguera-Galindo, D. O.
Aguilar-Lemarroy, A.
Jave-Suárez, L. F.
Torres-González, L. A.
González-Solís, J. L.
author_facet Torre-Gutiérrez, L. G. De la
Martínez-Zérega, B. E.
Oseguera-Galindo, D. O.
Aguilar-Lemarroy, A.
Jave-Suárez, L. F.
Torres-González, L. A.
González-Solís, J. L.
author_sort Torre-Gutiérrez, L. G. De la
collection PubMed
description In this paper, breast cancer patients were monitored throughout their chemotherapy treatments (CHT), with blood serum sample Raman spectroscopy and multivariate analysis, approximately for a year. First of all, we discriminate between healthy and clinically diagnosed breast cancer patients. Breast cancer detection in terms of sensitivity and specificity were 87.14% and 90.55% respectively. Although no shifts of peaks in mean spectrum of samples from breast cancer patients were found with respect to the mean spectrum from control patients, some peaks did show clear differences in intensity, the greatest disparities found at 509, 545, 1063, 1103, 1338, 1556, 1083 and 1449 cm(− 1) are associated with amino acids and phospholipid, 1246 and 1654 cm(− 1), corresponding to amide III and I, respectively. Other peaks of interest encountered at 450, 661, 890, 917 and 1405 cm(− 1) are associated to glutathione. Then, 6 breast cancer patients were monitored during their chemotherapy treatments, the results were in complete correspondence with their medical records, enabling a detailed study of the evolution of each patient’s cancer. A special interest arose in the possible correlation between the intensity of Raman peak, 450 cm(− 1), corresponding to glutathione and evolution of cancer throughout CHT, i.e., glutathione appears to be a good candidate as breast cancer biomarker. The results confirmed that Raman spectroscopy and PCA are, not only a good support to current breast cancer detection techniques, but could also be excellent techniques to monitor more efficiently breast cancer patients undergoing CHT, using blood serum samples which are a lot less invasive than other methods.
format Online
Article
Text
id pubmed-9562073
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer London
record_format MEDLINE/PubMed
spelling pubmed-95620732022-10-14 Breast cancer chemotherapy treatment monitoring based on serum sample Raman spectroscopy Torre-Gutiérrez, L. G. De la Martínez-Zérega, B. E. Oseguera-Galindo, D. O. Aguilar-Lemarroy, A. Jave-Suárez, L. F. Torres-González, L. A. González-Solís, J. L. Lasers Med Sci Original Article In this paper, breast cancer patients were monitored throughout their chemotherapy treatments (CHT), with blood serum sample Raman spectroscopy and multivariate analysis, approximately for a year. First of all, we discriminate between healthy and clinically diagnosed breast cancer patients. Breast cancer detection in terms of sensitivity and specificity were 87.14% and 90.55% respectively. Although no shifts of peaks in mean spectrum of samples from breast cancer patients were found with respect to the mean spectrum from control patients, some peaks did show clear differences in intensity, the greatest disparities found at 509, 545, 1063, 1103, 1338, 1556, 1083 and 1449 cm(− 1) are associated with amino acids and phospholipid, 1246 and 1654 cm(− 1), corresponding to amide III and I, respectively. Other peaks of interest encountered at 450, 661, 890, 917 and 1405 cm(− 1) are associated to glutathione. Then, 6 breast cancer patients were monitored during their chemotherapy treatments, the results were in complete correspondence with their medical records, enabling a detailed study of the evolution of each patient’s cancer. A special interest arose in the possible correlation between the intensity of Raman peak, 450 cm(− 1), corresponding to glutathione and evolution of cancer throughout CHT, i.e., glutathione appears to be a good candidate as breast cancer biomarker. The results confirmed that Raman spectroscopy and PCA are, not only a good support to current breast cancer detection techniques, but could also be excellent techniques to monitor more efficiently breast cancer patients undergoing CHT, using blood serum samples which are a lot less invasive than other methods. Springer London 2022-10-14 2022 /pmc/articles/PMC9562073/ /pubmed/36239879 http://dx.doi.org/10.1007/s10103-022-03646-5 Text en © The Author(s), under exclusive licence to Springer-Verlag London Ltd., part of Springer Nature 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article
Torre-Gutiérrez, L. G. De la
Martínez-Zérega, B. E.
Oseguera-Galindo, D. O.
Aguilar-Lemarroy, A.
Jave-Suárez, L. F.
Torres-González, L. A.
González-Solís, J. L.
Breast cancer chemotherapy treatment monitoring based on serum sample Raman spectroscopy
title Breast cancer chemotherapy treatment monitoring based on serum sample Raman spectroscopy
title_full Breast cancer chemotherapy treatment monitoring based on serum sample Raman spectroscopy
title_fullStr Breast cancer chemotherapy treatment monitoring based on serum sample Raman spectroscopy
title_full_unstemmed Breast cancer chemotherapy treatment monitoring based on serum sample Raman spectroscopy
title_short Breast cancer chemotherapy treatment monitoring based on serum sample Raman spectroscopy
title_sort breast cancer chemotherapy treatment monitoring based on serum sample raman spectroscopy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562073/
https://www.ncbi.nlm.nih.gov/pubmed/36239879
http://dx.doi.org/10.1007/s10103-022-03646-5
work_keys_str_mv AT torregutierrezlgdela breastcancerchemotherapytreatmentmonitoringbasedonserumsampleramanspectroscopy
AT martinezzeregabe breastcancerchemotherapytreatmentmonitoringbasedonserumsampleramanspectroscopy
AT osegueragalindodo breastcancerchemotherapytreatmentmonitoringbasedonserumsampleramanspectroscopy
AT aguilarlemarroya breastcancerchemotherapytreatmentmonitoringbasedonserumsampleramanspectroscopy
AT javesuarezlf breastcancerchemotherapytreatmentmonitoringbasedonserumsampleramanspectroscopy
AT torresgonzalezla breastcancerchemotherapytreatmentmonitoringbasedonserumsampleramanspectroscopy
AT gonzalezsolisjl breastcancerchemotherapytreatmentmonitoringbasedonserumsampleramanspectroscopy